CG Oncology (CGON) vs Immunovant (IMVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Immunovant (IMVT) has outperformed CG Oncology (CGON) over the past year, gaining 98.9% versus a gain of 64.2%. Immunovant is the larger company by market cap ($6.62 billion vs $5.53 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | IMVT |
|---|---|---|
| Share price | $62.38 | $32.04 |
| Market cap | $5.53B | $6.62B |
| 1-day change | -1.98% | -0.22% |
| YTD return | +50.24% | +26.04% |
| 1-year return | +64.16% | +98.88% |
| 5-year return | — | +267.43% |
| EPS (TTM) | $-2.69 | $-2.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | — |
| Revenue growth (YoY) | +254.70% | — |
| Net income (latest FY) | $-161.00M | $-505.61M |
| Operating margin | -4722.13% | — |
| Net margin | -3985.02% | — |
| 52-week high | $80.97 | $45.42 |
| 52-week low | $35.80 | $16.04 |
| Distance from 52-week high | -22.96% | -29.46% |
| Analyst consensus | none | buy |
| Avg. price target upside | +46.01% | +52.56% |
| Average volume | 899.28K | 1.23M |
| Shares outstanding | 88.64M | 206.55M |
| Employees | 142 | 315 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMVT has outperformed CGON by 34.7 percentage points over the past year.
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
CGON vs IMVT FAQ
Which is bigger, CG Oncology or Immunovant?
Immunovant (IMVT) is larger, with a market capitalization of $6.62B compared with $5.53B for CG Oncology (CGON).
Which stock has performed better over the past year, CGON or IMVT?
IMVT returned +98.88% over the past 12 months, compared with +64.16% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Immunovant in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.